Gene therapy gel aims to stop skin cancer from coming back in RDEB patients

NCT ID NCT06731933

Recruiting now Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether a gene therapy gel called BVEC can reduce the return of squamous cell carcinoma (a type of skin cancer) in people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic condition that causes fragile, blistering skin. The gel is applied to the skin after cancer removal to try to normalize the tissue and prevent recurrence. The study involves 16 adults in the US and Italy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Beremagene geperpavec (BVEC) - a gene therapy gel applied to the skin
What this could lead to: If it works, this could reduce the chance of skin cancer coming back after surgery in people with RDEB, potentially extending their lives.
What could go wrong: This is a small early-phase trial with only 16 people, so results may not apply to everyone. The gel is only tested on specific skin spots, and it may not prevent new cancers elsewhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

recessive dystrophic epidermolysis bullosa squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

Azienda Ospedliero-Universitaia
RECRUITING

Bari, Italy
Stanford University
RECRUITING

Redwood City, California, 94063, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.